Premium
Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients
Author(s) -
Dupuis L. Lee,
Boodhan Sabrina,
Sung Lillian,
Portwine Carol,
Hain Richard,
McCarthy Patricia,
Holdsworth Mark
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23114
Subject(s) - medicine , guideline , blood cancer , cancer , pediatric cancer , intensive care medicine , oncology , pathology
Abstract This guideline provides clinicians caring for children with an approach to assessing the acute emetogenic potential of antineoplastic therapies. It was developed by an international, inter‐professional panel of clinicians and researchers using AGREE and CAN‐ADAPTE methods. The emetogenicity of antineoplastic agents was evaluated and ranked as high, moderate, low, or minimal. The emetogenicity of multiple‐agent and multiple‐day antineoplastic therapy was also classified. Gaps in the evidence used to underpin the guideline recommendations were identified. The contribution of this guideline to the prevention of antineoplastic‐induced nausea and vomiting in individual children about to receive antineoplastic therapy requires prospective evaluation. Pediatr Blood Cancer 2011; 57: 191–198. © 2011 Wiley‐Liss, Inc.